This white paper analyzes the evolving landscape of early phase clinical trials, the uncertainties compelling investors to be cautious, and strategies to navigate these challenges for quicker treatment delivery to patients via seamless phase I/II and model-informed drug development. It covers advances in innovative trial methodologies—including adaptive and hybrid designs and MIDD approaches—empowering sponsors to make better-informed go/no-go decisions earlier while improving safety and efficiency.